Original reporting and analysis on the stories shaping biotech.
Incyte just dropped $1.25 billion (with another $750M on the table) to acquire a single drug for a bleeding disorder most people have never heard of. The bet says more about Incyte's post-Jakafi panic than it does about von Willebrand disease.
The FDA just approved the first entirely new class of ADHD medication in decades. Centanafadine hits all three neurotransmitters, not just the usual two, and that serotonin twist could reshape treatment for millions of patients.
GSK is spending $10.6 billion to buy Nuvalent and its two experimental lung cancer drugs, neither of which is approved yet. It's the company's biggest acquisition in over a decade, and it tells you everything about where Big Pharma thinks the money is headed.
Hackers didn't just hit Novo Nordisk's corporate systems — they got into clinical trial patient data. With claims of 1.3 terabytes stolen and a $25 million ransom demand, this breach exposes how vulnerable drug development's most sensitive data really is.
Roche just advanced the first AI-discovered drug target from its $12 billion Recursion partnership into a neurodegenerative disease program. In a field with a 99% failure rate, it's either a breakthrough moment for AI-driven drug discovery or the most expensive science experiment in history.
Roche is paying up to $1.05 billion to acquire PathAI, the company whose software reads cancer tissue slides with artificial intelligence. It's the biggest signal yet that computational pathology is moving from science project to standard of care.
Moderna's mRNA flu vaccine just got a unanimous thumbs-up from the FDA's advisory committee. If approved by August 5, it would be the first mRNA flu shot ever licensed in the U.S., opening a multibillion-dollar market that could redefine Moderna's future beyond COVID.
Takeda's AI-designed psoriasis pill zasocitinib just beat BMS's Sotyktu by more than 2.5x on complete skin clearance in a head-to-head Phase 3 trial. It might be the strongest proof yet that AI-designed drugs can outperform conventionally discovered ones in humans.
Charles River Laboratories just raised its profit forecast on surging biotech demand, and the implications go way beyond one company's earnings. The biggest preclinical CRO's order book might be the clearest sign yet that biotech's funding winter is finally thawing.
Vertex Pharmaceuticals just made its largest acquisition ever, paying a 102% premium to buy Crinetics Pharmaceuticals for $10 billion in cash. The deal catapults Vertex into endocrinology with the first oral pill for acromegaly and a pipeline that analysts are calling a 'white space blockbuster opportunity.'
The FDA just dropped its biggest clinical trial overhaul in decades under Operation TrialBlazer, targeting everything from IND submissions to evidence standards. If it works as planned, the path from lab to first human dose could shrink by 6 to 12 months.
Scribe Therapeutics just raised $155 million in its Nasdaq debut, betting that a single gene-editing injection can replace daily cholesterol pills forever. Co-founded by Nobel laureate Jennifer Doudna, the company is Wall Street's newest test of whether early-stage CRISPR platforms can still command serious money.
Genentech inked a $490 million breast cancer deal with Astex Pharmaceuticals and laid off 103 scientists in the same breath. It's the starkest example yet of Big Pharma's new playbook: spend big on external bets, cut deep on the inside.
ImmVira's oncolytic virus MVR-T3011 just posted a 100% complete response rate in bladder carcinoma in situ at 9 months. The catch? The cohort is tiny. Here's why urologists are watching closely anyway.
Two gene-editing companies born from the same Harvard lab just fought over who gets to treat a rare liver disease. The arbitration ruling has big implications for how the entire CRISPR ecosystem draws battle lines.
Can you sue a drug company for not inventing fast enough? The California Supreme Court just answered that question in a 6–1 ruling that wiped out 24,000 cases against Gilead and sent shockwaves through pharma's legal landscape.
Osteosarcoma hasn't seen a meaningful new treatment option in over 40 years. Hansoh Pharma's B7-H3 antibody-drug conjugate just broke that streak with a Phase III win, and the implications for pediatric oncology and the red-hot ADC space are hard to ignore.
GSK is walking away from its $2.2 billion neurodegeneration partnership with Alector after both drugs failed in clinical trials, writing off $700 million. It's the latest (and most expensive) sign that big pharma's patience for brain disease bets is running thin.
Curium just agreed to buy Lantheus Holdings for up to $8 billion, making it the largest pure-play radiopharmaceutical deal in history. The megadeal signals that nuclear medicine's transformation of cancer care is no longer a niche bet; it's a full-blown arms race.
The scientist who launched Project Lightspeed and delivered the world's first mRNA COVID vaccine is leaving BioNTech to start something new. His replacement? A dealmaking CEO who quadrupled Sobi's revenue in nine years.
A Swiss biotech just earned the first-ever FDA Fast Track for a drug targeting the genome's 'dark side' in heart disease. HTX-001 goes after a rogue piece of non-coding RNA to reprogram scarred heart cells, and it could rewrite the rules for an entire class of medicine.
Wave Life Sciences just started dosing a new obesity drug that targets a completely different pathway than GLP-1s. WVE-007 silences a liver gene to burn fat while preserving muscle, and the early data are turning heads.
Join thousands of biotech professionals who start their day with our free, daily briefing.